ВОИС - Поиск по национальным патентным фондам и фондам PCT

1.WO/2022/098525INTRANASAL ANTIVIRAL THERAPY FOR MUCOSAL PROTECTION AGAINST VIRUS INFECTIONS

WO - 12.05.2022

Класс МПК A61K 31/717 № заявки PCT/US2021/056392 Заявитель BRAVADO PHARMACEUTICALS, LLC Изобретатель MCMILLAN, Brian

A topical intranasal antiviral composition for protecting against virus infections. The composition comprises an antigen binder and a pharmaceutical suspender material to allow effective delivery into the nasal cavity. Examples of materials that could be used in the pharmaceutical suspender are microcrystalline cellulose or sodium carboxymethylcellulose (Na∙CMC). One particular target for the antigen binder could be SARS-CoV-2. For example, the antigen binder could target the S1 subunit of SARS-CoV-2. The composition could be made by a process in which the pharmaceutical vehicle is prepared, and then the antigen binder is added to the pharmaceutical vehicle to make a bioactive mixture, and then adding solid sodium chloride to the bioactive mixture. Also disclosed are methods of protection against virus infection using the intranasal antiviral composition. For example, in the case of SARS-CoV-2, the antigen binder would block the virus particles from attaching to ACE2 receptors on host cells of the nasal mucosa or nasopharynx. This blocking action would protect against virus infection.

2.WO/2022/099260COMPOSITIONS AND METHODS FOR TARGETING THE INTERACTION OF HOST MYO5B+D AND CORONAVIRUS M PROTEINS

WO - 12.05.2022

Класс МПК A61K 39/215 № заявки PCT/US2021/072201 Заявитель VANDERBILT UNIVERSITY Изобретатель TANGY, Frédéric

Disclosed herein is a method for treating or preventing a coronavirus infection in a subject that involves administering to the subject an effective amount of a composition comprising an agent that disrupts the binding of coronavirus membrane glycoprotein (M protein) and Myosin Vb protein (MYO5B). Also disclosed herein is a method for identifying an agent for treating or preventing a coronavirus infection that involves providing a system comprising coronavirus membrane glycoprotein (M protein) and human Myosin Vb protein (MYO5B) with conditions suitable for binding of the M protein and MYO5B; contacting the system with a candidate agent; and assaying the system for binding of M protein and MYO5B.

3.WO/2022/094287MULTIVALENT PARTICLES COMPOSITIONS AND METHODS OF USE

WO - 05.05.2022

Класс МПК C12Q 1/70 № заявки PCT/US2021/057368 Заявитель ACHELOIS BIOPHARMA, INC. Изобретатель CHEN, Chang-Zheng

Provided herein are multivalent particles and compositions of multivalent particles for blocking viral infection.

4.WO/2022/089233RECOMBINANT SPIKE PROTEIN, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

WO - 05.05.2022

Класс МПК C07K 14/165 № заявки PCT/CN2021/124364 Заявитель SHANGHAI ZERUN BIOTECHNOLOGY CO., LTD. Изобретатель AN, Jiao

Disclosed in the present invention are a recombinant spike protein, an encoding nucleic acid therefor, a preparation method therefor, a vaccine composition comprising the recombinant spike protein, and an application thereof. The recombinant spike protein can be used to prevent SARS-CoV-2 infection or a disease caused by SARS-CoV-2 infection.

5.WO/2022/094343ANTI-SARS-COV-2 ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS

WO - 05.05.2022

Класс МПК C07K 16/10 № заявки PCT/US2021/057452 Заявитель ADAPTIVE BIOTECHNOLOGIES CORPORATION Изобретатель YUSKO, Erik

Provided are antibodies that specifically bind a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antigen. Nucleic acids that encode one or both of the variable chain polypeptides of an antibody of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual in need thereof, e.g., an individual having or suspected of having a SARS-CoV-2 infection, a therapeutically effective amount of an antibody of the present disclosure.

6.20220135626MULTIVALENT PARTICLES COMPOSITIONS AND METHODS OF USE

US - 05.05.2022

Класс МПК C07K 14/165 № заявки 17514572 Заявитель Achelois BioPharma, Inc. Изобретатель Chang-Zheng Chen

Provided herein are multivalent particles and compositions of multivalent particles for blocking viral infection.

7.20220133880NOVEL SARS-COV-2 ANTIGENS AND USES THEREOF

US - 05.05.2022

Класс МПК A61K 39/215 № заявки 17512902 Заявитель MASSACHUSETTS INSTITUTE OF TECHNOLOGY Изобретатель J. Christopher LOVE

The present disclosure relates to, inter alia, variants of the receptor binding domain of a coronavirus (e.g., SARS-CoV-2) having increased immunogenicity and reduced aggregation, and the use of the RBD variants in methods for preventing infection of the coronavirus.

8.WO/2022/089471β-CORONAVIRUS MULTIMERIC ANTIGEN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

WO - 05.05.2022

Класс МПК C07K 19/00 № заявки PCT/CN2021/126639 Заявитель INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES Изобретатель GAO, Fu

Provided are a β-coronavirus multimeric antigen, a preparation method therefor and an application thereof, the amino acid sequence of the β-coronavirus multimeric antigen comprising: some amino acid sequences or all amino acid sequences of receptor-binding domains (RBDs) of a plurality of spike proteins of a β-coronavirus, the spike proteins directly forming a series connection or being in series by connecting to amino acid sequences, the some amino acid sequences or all amino acid sequences of the RBDs of the serially connected spike proteins being derived from the same β-coronavirus, and the plurality being an integer≥3. A SARS‑CoV‑2 RBD multimer may be stably expressed, and an immune response may be strongly induced after immunizing mice; in addition, a neutralizing antibody titer produced by the induced mice is significantly different from that of a SARS‑CoV‑2 RBD dimer.

9.WO/2022/094622POLYPEPTIDES FOR DETECTION AND TREATMENT OF SARS-COV-2

WO - 05.05.2022

Класс МПК C07K 16/10 № заявки PCT/US2021/072152 Заявитель THE UNIVERSITY OF CHICAGO Изобретатель KOSSIAKOFF, Anthony

Aspects of the present disclosure relate to polypeptides that specifically bind to a SARS-CoV-2 spike protein, and to methods of use for treatment, prevention, and diagnosis of a SARS-CoV-2 infection. Certain aspects are directed to antibodies and fragments thereof, including Fabs, configured to bind to various epitopes within the receptor binding domain (RBD) of a SARS-CoV-2 spike protein. Compositions, kits, and methods for detection of SARS-CoV-2 are also disclosed.

10.WO/2022/094011NOVEL SARS-COV-2 ANTIGENS AND USES THEREOF

WO - 05.05.2022

Класс МПК C07K 14/165 № заявки PCT/US2021/056946 Заявитель MASSACHUSETTS INSTITUTE OF TECHNOLOGY Изобретатель LOVE, Christopher, J.

1 / 104

Перейти к вводу поиска	`CTRL` + `SHIFT` +
Перейти к результатам (выбранная запись)	`CTRL` + `SHIFT` +
Перейти к результатам (выбранная вкладка)	`CTRL` + `SHIFT` +
Перейти на следующую страницу	`CTRL` +
Перейти на предыдущую страницу	`CTRL` +

Перейти к следующей записи / изображению	/
Перейти к предыдущей записи / изображению	/
Прокрутить вверх	`Page Up`
Прокрутить вниз	`Page Down`
Прокрутить до верха	`CTRL` + `Home`
Прокрутить до низа	`CTRL` + `End`

Идет обработка

Переходы на национальную фазу

Файл международного органа

Настройки

Обратная связь

Перейти к заявке

Сохранить запрос

Дерево запросов

Уточнить параметры

Полный запрос

Ярлыки к параллельному просмотру

Анализ

Перейти к следующей вкладке
Перейти к предыдущей вкладке